Navidea Biopharma (NAVB) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Navidea Biopharma (NAVB) Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis
November 12, 2020 4:03 PM ESTNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from analysis of subjects who have completed Arm 3 of the Companys ongoing NAV3-31 Phase 2B study. These data further corroborate Navideas hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in patients with active rheumatoid arthritis (RA) and that this imaging can provide an early indicator of treatment efficacy.
Navideas NAV3-31 Phase 2B trial titled Evaluation of the Precision and Sensitivity of... More
